Back to Search
Start Over
Case reports: practical experience with efalizumab in hand and foot psoriasis.
- Source :
-
Journal of drugs in dermatology : JDD [J Drugs Dermatol] 2007 Dec; Vol. 6 (12), pp. 1224-30. - Publication Year :
- 2007
-
Abstract
- Psoriasis of the hands and feet is highly debilitating and difficult to treat. It may be of a plaque-or pustular-type, or a combination of the two. Efalizumab (Raptiva, Genentech Inc), a humanized monoclonal antibody that inhibits critical T cell-mediated processes, is approved by the FDA for the treatment of adult patients with chronic moderate to severe plaque psoriasis. We present the cases of 7 patients who suffered from extensive hand and foot psoriasis recalcitrant to treatment. Each patient was treated with 1 mg/kg/wk of efalizumab and responded rapidly to treatment with favorable results appearing within 1 to 4 months. Patients were able to resume previous work responsibilities and no longer suffered from difficulties with ambulation. Efalizumab was effective for the rapid treatment of these 7 patients with psoriasis of the hands and feet.
- Subjects :
- Adult
Aged
Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal, Humanized
Female
Foot Dermatoses pathology
Hand Dermatoses pathology
Humans
Immunologic Factors adverse effects
Injections
Male
Middle Aged
Psoriasis pathology
Antibodies, Monoclonal therapeutic use
Foot Dermatoses drug therapy
Hand Dermatoses drug therapy
Immunologic Factors therapeutic use
Psoriasis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1545-9616
- Volume :
- 6
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Journal of drugs in dermatology : JDD
- Publication Type :
- Academic Journal
- Accession number :
- 18189064